- Senior Business Advisor | Sector Team
Imagination is more important than knowledge for knowledge is limited, whereas imagination embraces the entire world
Dr. Jean-Paul Castaigne has already had a prolific international career in the field of life sciences. He is currently President and CEO of Rytvel Biotech, a company currently developing medication to prevent and treat the consequences of preterm birth in humans. Prior to this position, he headed Angiochem from 2006 to 2015, where he spearheaded several clinical trials, raised over $27 million in funding and negotiated licences with multinationals in the industry. These licences generated investments of over $200 million and royalties that may exceed $500 million. Earlier in his career, he was Vice President and CSO (Chief Science Officer) at Conjuchem (Montreal) and Vice President, Global R & D at Groupe Fournier SA (France). He also held key positions within the Novartis Group for over 10 years, including roles in Sandoz in the Philippines, France and Canada. During this period, he specialized in regulatory affairs. Jean-Paul was awarded his MD degree by the University of Paris in 1975 and became professor of oncology and respiratory medicine there in 1978. In 1987, he graduated from HEC Paris with an MBA. In addition to his professional management responsibilities, Dr. Castaigne also sits on several advisory committees and boards of directors, including Leucofondation, Bio-Québec and Asmacure. Jean-Paul Castaigne has also published or co-published over a hundred scientific publications and co-invented over 20 patent applications.
He specializes in:
- Clinical trial process management
- Licence negotiation on an international scale
- Development financing for new medication
- Regulatory affairs